Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-2878
Akhmetshina, A; Dees, C; Pileckyte, M; Maurer, B; Axmann, R; Jüngel, A; Zwerina, J; Gay, S; Schett, G; Distler, O; Distler, J H W (2008). Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB Journal, 22(7):2214-2222.
|PDF - Registered users only|
Abelson kinase (c-abl) and platelet-derived growth factor (PDGF) are key players in the pathogenesis of systemic sclerosis (SSc). The aim of the present study was to evaluate the antifibrotic potential of dasatinib and nilotinib, 2 novel inhibitors of c-abl and PDGF, which are well tolerated and have recently been approved. Dasatinib and nilotinib dose-dependently reduced the mRNA and protein levels of extracellular matrix proteins in human stimulated dermal fibroblasts from SSc patients (IC(50) of 0.5-2.0 nM for dasatinib and 0.8-2.5 nM for nilotinib). In a mouse model of bleomycin-induced dermal fibrosis, dasatinib and nilotinib potently reduced the dermal thickness, the number of myofibroblasts, and the collagen content of the skin in a dose-dependent manner at well-tolerated doses. These data indicate that dasatinib and nilotinib potently inhibit the synthesis of extracellular matrix in vitro and in vivo at biologically relevant concentrations. Thus, we provide the first evidence that dasatinib and nilotinib might be promising drugs for the treatment of patients with SSc.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > Center for Integrative Human Physiology|
04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine
|DDC:||570 Life sciences; biology|
610 Medicine & health
|Deposited On:||25 Aug 2008 15:31|
|Last Modified:||27 Nov 2013 23:54|
|Publisher:||Federation of American Societies for Experimental Biology|
|Citations:||Web of Science®. Times Cited: 80|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page